Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV045
    • TRV250
    • TRV734
  • Products
    • OLINVYKâ„¢ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
    • IRS Form 8937
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena Reports First Quarter 2015 Financial Results and Provides a Corporate Update

May 07, 2015 7:00am EDT

Trevena Appoints Carrie Bourdow as Chief Commercial Officer

May 04, 2015 7:00am EDT

Trevena CEO to present at the 14th Annual Needham Healthcare Conference

Apr 08, 2015 7:00am EDT

Trevena CMO to Present at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference

Mar 18, 2015 4:30pm EDT

Trevena Reports Full Year 2014 Financial Results

Mar 18, 2015 7:00am EDT

Trevena to Host Conference Call on March 18th to Discuss Full Year 2014 Financial Results

Mar 11, 2015 7:00am EDT

Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure

Mar 09, 2015 7:00am EDT

Trevena CEO to Present at the Barclays Global Healthcare Conference

Mar 04, 2015 7:00am EST

Trevena CEO to Present at the Cowen and Company 35th Annual Health Care Conference

Feb 24, 2015 7:00am EST

Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain

Feb 09, 2015 7:00am EST
RSS
  • Prev
    • 1...
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • ...31
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap